Cell line · CVCL_1566
Papers56
1 to 20 of 56
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K. | NPJ Vaccines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| scResponse: A Rank-Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single-Cell Data. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| C1RL-AS1/microRNA-424-5p/adrenoceptor β2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| SARS-CoV-2 Spreads through Cell-to-Cell Transmission. | bioRxiv | 2021 | Its Methods give the RRID and name the line | PubMed | |
| 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1566/papers